<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020940</url>
  </required_header>
  <id_info>
    <org_study_id>FM-P5-2016072201-1</org_study_id>
    <nct_id>NCT03020940</nct_id>
  </id_info>
  <brief_title>The Clinical Trial of Cefuroxime Axetil Dispersible Tablets</brief_title>
  <official_title>100000 Cases Real World Research of the Safety and Efficacy Revaluation of Cefuroxime Axetil Dispersible Tablets After Listing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Famous Medical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Famous Medical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. National, large-scale, standardized, standardized, real-world research;&#xD;
&#xD;
        2. Prospective, single - arm open, non - interventional, registration, multi - center&#xD;
           clinical study;&#xD;
&#xD;
        3. in the use of cefuroxime axetil dispersible tablets in the hospital, according to the&#xD;
           principle of voluntary selection of 200;&#xD;
&#xD;
        4. registration of the use of cefuroxime axetil dispersion tablets patients;&#xD;
&#xD;
        5. Target sample size of 100,000 cases;&#xD;
&#xD;
        6. Exemption from informed consent for ethical review applications;&#xD;
&#xD;
        7. Antibiotic drug safety re-evaluation of large data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research purposes&#xD;
&#xD;
        1. To evaluate the safety of cefuroxime axetil dispersible tablets in the real world of the&#xD;
           widely used population,&#xD;
&#xD;
           Rare or even very rare, new, unanticipated adverse reactions, while revealing adverse&#xD;
           reactions&#xD;
&#xD;
           Should be susceptible to risk factors and susceptible populations.&#xD;
&#xD;
        2. To evaluate the efficacy of cefuroxime axetil dispersible tablets in the treatment of&#xD;
           the relevant site of infection, including&#xD;
&#xD;
           Including empirical therapy and targeted therapy, to further evaluate the widespread use&#xD;
           of cefuroxime dispersible tablets&#xD;
&#xD;
           The validity of the crowd in the real world.&#xD;
&#xD;
        3. To investigate the clinical application of cefuroxime axetil dispersible tablets for the&#xD;
           safety management of drug use.&#xD;
&#xD;
           Clinical management should provide more clinical clues and basis.&#xD;
&#xD;
        4. For the relevant treatment areas of guidance and consensus revision, clinical pathway&#xD;
           design provides a reference.&#xD;
&#xD;
        5. To further improve the safety of cefuroxime axetil dispersion tablets level, the basic&#xD;
           medical security capabilities and Market vitality.&#xD;
&#xD;
      Study end point&#xD;
&#xD;
        1. The main study endpoint:&#xD;
&#xD;
             -  Security;&#xD;
&#xD;
             -  Effectiveness.&#xD;
&#xD;
        2. Secondary study endpoint:&#xD;
&#xD;
             -  Extensive use of population characteristics;&#xD;
&#xD;
             -  Clinical drug characteristics;&#xD;
&#xD;
             -  Appropriate characteristics of the crowd;&#xD;
&#xD;
             -  Adverse reactions susceptible population characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial clearance</measure>
    <time_frame>1 to 14 days after the use of Cefuroxime Axetil Dispersible Tabletsï¼Œ</time_frame>
    <description>1.clear 2.Assume purge 3.Not cleared 4.Assume not cleared 5.Partially cleared 6.replace 7.Re-infection 8.Colonization 9.Can not be evaluated</description>
  </primary_outcome>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Infectious Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime Axetil Dispersible Tablets</intervention_name>
    <description>Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.&#xD;
Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.&#xD;
Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.&#xD;
Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prescription of cefuroxime axetil dispersible tablets in patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prescription of cefuroxime axetil dispersible tablets in patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaojun Ma, doctor</last_name>
    <phone>13911378823</phone>
    <email>drmaxiaojun@sina.com</email>
  </overall_contact>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>January 6, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

